Observational Registry Study of Chinese Patients Treated With Revlimid (Lenalidomide)
Conditions
Multiple Myeloma
Conditions: official terms
Multiple Myeloma - Neoplasms, Plasma Cell
Conditions: Keywords
Revlimid, lenalidomide, multiple myeloma, PFS, Response Rates
Study Type
Observational
Study Phase
N/A
Study Design
Observational Model: Cohort, Time Perspective: Prospective
Intervention
Name: Revlimid (lenalidomide)
Type: Drug
Overall Status
Not yet recruiting
Summary
The primary objective of this study is to document efficacy and safety data in a real-world setting of Chinese multiple myeloma patients who have received at least one prior therapy treated with REVLIMID (lenalidomide).
Detailed Description
This registry is prospective, multi-center, observational study and will collect efficacy and safety data on multiple myeloma adult patients who have received at least one prior therapy and take REVLIMID as part of standard care associated with patients' treatment in order to characterize the use, efficacy and outcomes of REVLIMID treatment.

The registry will capture data from 600 patients being prescribed REVLIMID in specified hospitals and all patients will be followed in the registry for two years after enrollment of the last patient.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

- Must understand and voluntarily sign written informed consent At least 18 years old at the time of signing informed consent Diagnosed with Multiple Myeloma Must have received at least one prior Multiple Myeloma treatment at the time of signing informed consent

Exclusion Criteria:

- None
Locations
Beijing Hospital
Beijing, China
Status: Not yet recruiting
Peking Chao-Yang Hospital
Beijing, China
Status: Not yet recruiting
Peking University People's Hospital
Beijing, China
Status: Not yet recruiting
People's Liberation Army Hospital 307
Beijing, China
Status: Not yet recruiting
The Fisrt Hospital Of Jilin University
Changchun, China
Status: Not yet recruiting
Xiangya Hospital Central-South University
Changsha, China
Status: Not yet recruiting
Xinqiao Hospital, 3rd Military Medical University
Chongqing, China
Status: Not yet recruiting
NanFang Hospital of China Southern Medical University
Guangzhou, China
Status: Not yet recruiting
The First Affliated Hospital of Anhui Medical University
Hefei, China
Status: Not yet recruiting
Qilu Hospital of Shandong University
Jinan, China
Status: Not yet recruiting
The Affiliated Hospital of Mecical College Qingdao University
Qingdao, China
Status: Not yet recruiting
Shanghai Changzhen Hospital
Shanghai, China
Status: Not yet recruiting
The Second Affiliated Hospital Of China Medical University
Shenyang, China
Status: Not yet recruiting
The First Affiliated Hospital of Suzhou University
Suzhou, China
Status: Not yet recruiting
People's Hospital of Xinjiang Uygur Autonomous Region
Urumqi, China
Status: Not yet recruiting
Tongji Medical College Huazhong University of Science & Technology
Wuhan, China
Status: Not yet recruiting
Wuhan Union Hospital of Tongji Medical College of Huazhong University of Science & Technology
Wuhan, China
Status: Not yet recruiting
Start Date
September 2013
Completion Date
January 2018
Sponsors
Celgene Corporation
Source
Celgene Corporation
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page